The GLP-1 Economy — Digest
TL;DR
The oral share-shift story hit a pause button: Foundayo fell 9.9% sequentially while the Wegovy pill held near 180K, meaning last cycle's "30% threshold" watch moved further away, not closer. Novo's structural position worsened on a second front — the EPO revoked a core semaglutide formulation patent, putting EU exclusivity at risk as early as 2031. And the amylin race got its first hard Phase 2b scoreboard: Lilly's EloraTZP at 23.3% weight loss in the diabetic-obesity population, with Phase 3 planned by year-end.
The Oral Ramp Was a Spike, Not a Trend
Last cycle's clean Foundayo acceleration now looks partly like a one-week distortion.
"scripts for all major GLP-1s declined last week across diabetes and obesity care, save for Lilly's Zepbound KwikPen"
— Fierce Pharma's Oral GLP-1 Tracker, Oct 9
The specifics: Foundayo posted 57,920 scripts in week 26, down 9.9% sequentially from the 64,268 surge, while Novo's Wegovy pill slipped only 1.4% to ~179.5K — still trapped in the same 179–184K band it has occupied for weeks (Fierce Pharma tracker). That means Lilly's 26% oral share receded rather than advanced toward the 30% trigger flagged in the previous digest, and the softness was class-wide — Zepbound total scripts dipped below 800K, and total Wegovy (pill plus injectable) fell 2.7% to 505.5K. Jefferies is modeling $208M in Foundayo Q3 sales, in line with consensus, so the pullback isn't a consensus-breaker yet (Fierce Pharma tracker).
What to watch: Lilly's Q3 earnings on October 29 — the first full quarter of the DTC/Medicare-Bridge ramp, and the read on whether the $149 starter pricing "elasticity experiment" re-accelerates scripts.
Novo's Patent Wall Is Coming Down Faster Than Planned
The exclusivity clock, not just the competitive clock, is now running against Novo.
"Under the patents that remain valid, market exclusivity for products containing semaglutide could expire as early as 2031"
— JUVE Patent
On October 8, the EPO Board of Appeal revoked EP 3 448 416 — the formulation patent behind Ozempic and Wegovy — reversing its own preliminary opinion, and critically, "there are no divisional applications within this patent family," so a protection stream that could have run to 2037 is gone (JUVE Patent). NVO closed at $38.64 on Oct 12, down 36.7% from its 52-week high at 9.45x trailing earnings (NVO market view). Novo's answer is a deal spree — over £4 billion announced for new weight-loss and cardiometabolic assets ahead of the expiries — but every revoked patent compresses the semaglutide cash-flow tail that has to fund that rebuild.
What to watch: Whether further EPO challenges in the semaglutide family land before CagriSema's Q4 FDA decision, which remains the nearer re-rating catalyst.
EloraTZP Sets the Amylin Bar — With an Asterisk
The amylin-combo race that defined EASD got its first decisive Phase 2b readout, and Lilly owns it.
"Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg"
— Eli Lilly press release
In the 48-week study of 367 adults with obesity and type 2 diabetes, the top dose delivered -23.3% body weight and -2.9% A1C versus -14.8% and -2.4% for tirzepatide alone — and per Fierce Biotech's EASD coverage, that tops Lilly's own triple agonist retatrutide in the T2D population, where efficacy attenuation is the norm (Lilly release; Fierce Biotech). The asterisk is tolerability: discontinuation due to adverse events ran 10.8%–27.0% in the EloraTZP arms versus 2.9% for tirzepatide alone, and Lilly says Phase 3 will use "an optimized escalation schedule" (Lilly release). With Novo's CagriSema FDA decision due in Q4, the amylin race now has parallel, comparable milestones — and a new watch thread is tracking Lilly's Phase 3 initiation by end of 2026.
What to watch: The EloraTZP Phase 3 initiation announcement and its titration design — whether the optimized schedule actually fixes the discontinuation problem determines if 23.3% is deliverable.
The Consumer Pivot Becomes Official Strategy
Both incumbents just reorganized around the idea that the moat is migrating from molecule potency to consumer experience.
"This is where serious condition prescription medication meets incredibly strong consumer demand"
— Novo CEO Mike Doustdar, Fierce Pharma
Novo unveiled a planned "Consumer Rx" segment at its September CMD and rebranded from "Novo Nordisk" to "Novo"; Lilly, meanwhile, posted a "Sr Director, Aesthetic Health External Innovation" role signaling a move into appearance-adjacent categories (Fierce Pharma). Doustdar conceded the efficacy gap plainly — "Mounjaro was launched later and demonstrated higher maximum weight-loss rates, leading the market to perceive it as a 'next-generation drug'" — and reframed the fight around fat-vs-muscle preservation, adherence, and orals, where he claims "no company prepares as many oral treatments as we do" (Chosun Ilbo). This is management-level confirmation that when efficacy differences compress, the battlegrounds become brand, DTC channels, and lifecycle adjacencies.
What to watch: Whether Lilly follows Novo with an explicit consumer-organization or aesthetics announcement of its own.
Public Payer Coverage Expands Where Commercial Retreated
The coverage map is splitting into negotiated-discount states and everyone else.
"Indiana Medicaid will pay $85.16 of the $245 monthly cost per person, thanks to contributions from the federal government and manufacturer discounts"
— Indiana Capital Chronicle
Governor Braun directed Indiana's Medicaid program — covering 1.9 million Hoosiers — to opt into the CMS BALANCE model, with Ricks endorsing the move and naming Foundayo and Zepbound explicitly (Indiana Capital Chronicle). The context makes the dynamic legible: only 13 state Medicaid programs covered GLP-1s for obesity at the start of 2026, down from 16, because standalone coverage collapses at list price — while the BALANCE model makes it viable by cutting net price to ~$85/month (ObesityIntel). Each opt-in converts a zero-reimbursement population into discounted volume for Lilly and Novo, building a political floor under pricing even as commercial employers pull back.
What to watch: Which states opt into BALANCE next — the eligibility criteria and timing for Indiana itself are still being finalized.
Small Caps: One Delivers, One Grinds
Viking bought time; Structure bled out. Viking started Part 2 of its VK2735 maintenance study — testing daily and weekly oral tablets, plus every-other-week and monthly subcutaneous dosing, to hold weight loss achieved via 21 weeks of weekly injection (PR Newswire; PR Newswire release) — but as ObesityIntel notes, "this is not the oral VK2735 Phase 3 programme," which remains guided to Q4 2026 and unannounced (ObesityIntel). The stock fell ~3% on the announcement; the market wants the registrational trial. Structure's slide, meanwhile, resolved the open thread: it's a grind, not a catalyst. GPCR printed a 52-week low of $25.56 with an RSI of 1, and ObesityIntel's dated check found "no dated corporate change" at Structure — or Lilly, Amgen, or Altimmune — between September 29 and October 7 (ObesityIntel). The repricing is the oral GLP-1 premium compressing as Foundayo scales at $149; the Q4 SWITCH and Body Composition readouts are now the binary events.
What to watch: Viking's oral VK2735 Phase 3 initiation before year-end — the watch stays open and inside its window.
What surprised us
- The Oct 2 Foundayo surge now looks like noise. A 21% spike that fully reverses a week later, in a class-wide down week, suggests payback or channel dynamics rather than a clean ramp — the "30% share" trigger from last cycle's digest got further away, not closer (Fierce Pharma tracker).
- The patent cliff is a 2031 story, not a 2037 story. Revoking a formulation patent with no divisionals — after the board had preliminarily leaned toward maintaining it — is the kind of reversal that should make Novo's remaining EU patent estate feel less secure than the docket suggests (JUVE Patent).
- The litigation overhang is big but inert. Roughly 4,025 actions in the gastroparesis MDL and ~247 in the NAION MDL, with no trial, no settlement, and a first bellwether expected late 2026–2027 — as ObesityIntel puts it, until a verdict attaches a number, "this is a dated calendar item, not a valuation input" (ObesityIntel).
- EloraTZP's tolerability asterisk is bigger than the headline suggests. Up to 27% AE discontinuation is a real deliverability problem, and Lilly's entire Phase 3 design bet is that optimized titration fixes it.
Open threads worth a vote
The GLP-1 Economy — Digest
Since last time
- Promoted — Amylin. Last cycle it was an EASD narrative with dueling cross-trial claims; now it has a hard Phase 2b scoreboard (Lilly's EloraTZP at 23.3%), a tolerability asterisk, and its own open thread. Also promoted: the oral VK2735 Phase 3 watch is now a formal open thread.
- Escalated — Novo's deterioration. Last cycle was a valuation discount; this cycle it's structural — the EPO revoked a core semaglutide formulation patent, putting EU exclusivity at risk as early as 2031. Also escalated: the oral share-shift story reversed (Foundayo fell 9.9% sequentially), and the Structure Therapeutics thread resolved.
- Demoted — Novo's stock slide. A full section last cycle; now a single data point inside the patent section ($38.64, down 36.7% from its 52-week high, 9.45x trailing). Pricing-as-weapon is likewise compressed — the $149 starter price survives as an "elasticity experiment" mention, but the channel-bifurcation detail is gone.
- Disappeared — Big Food's headwind (the Cornell 5–8% grocery finding, PepsiCo/Mondelez ranking, JPMorgan/Morgan Stanley adoption math — only retatrutide survives, as a comparator in the amylin section). Medicare Bridge specifics (~700K seniors, Ricks' 7-of-10 claim) and its open thread. All three of last cycle's "what surprised us" bullets (the Ro switch study, Lilly's cross-trial pooling, China molecule licensing). The Foundayo-30% thread was dropped from the thread list — absorbed into the body as paused, not closed.
- Unchanged — nothing; every section moved at least somewhat.
The Oral Ramp Was a Spike, Not a Trend — Escalated (direction reversed)
Last cycle's clean Foundayo acceleration now looks partly like a one-week distortion.
"scripts for all major GLP-1s declined last week across diabetes and obesity care, save for Lilly's Zepbound KwikPen"
— Fierce Pharma's Oral GLP-1 Tracker, Oct 9
Foundayo posted 57,920 scripts in week 26, down 9.9% from the 64,268 surge, while the Wegovy pill slipped only 1.4% to ~179.5K — still in the same 179–184K band it has occupied for weeks (Fierce Pharma tracker). Lilly's 26% oral share receded rather than advancing toward the 30% trigger flagged last cycle, and the softness was class-wide: Zepbound total scripts dipped below 800K, total Wegovy fell 2.7% to 505.5K. Jefferies models $208M in Foundayo Q3 sales, in line with consensus, so this isn't a consensus-breaker yet.
What to watch: Lilly's Q3 earnings on October 29 — the first full quarter of the DTC ramp, and the read on whether $149 starter pricing re-accelerates scripts.
Novo's Patent Wall Is Coming Down Faster Than Planned — New
The exclusivity clock, not just the competitive clock, is now running against Novo.
"Under the patents that remain valid, market exclusivity for products containing semaglutide could expire as early as 2031"
— JUVE Patent
On October 8, the EPO Board of Appeal revoked EP 3 448 416 — the formulation patent behind Ozempic and Wegovy — reversing its own preliminary opinion, and "there are no divisional applications within this patent family," so a protection stream that could have run to 2037 is gone (JUVE Patent). Novo's answer is a deal spree — over £4 billion announced for new weight-loss and cardiometabolic assets — but every revoked patent compresses the semaglutide cash-flow tail that has to fund the rebuild.
What to watch: Whether further EPO challenges in the semaglutide family land before CagriSema's Q4 FDA decision, still the nearer re-rating catalyst.
EloraTZP Sets the Amylin Bar — With an Asterisk — Promoted
The amylin-combo race got its first decisive Phase 2b readout, and Lilly owns it.
"Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg"
— Eli Lilly press release
In the 48-week study of 367 adults with obesity and type 2 diabetes, the top dose delivered -23.3% body weight and -2.9% A1C versus -14.8% and -2.4% for tirzepatide alone — and per Fierce Biotech's EASD coverage, that tops Lilly's own retatrutide in the T2D population, where efficacy attenuation is the norm (Lilly release; Fierce Biotech). The asterisk: AE discontinuations ran 10.8%–27.0% in EloraTZP arms versus 2.9% for tirzepatide alone, and Lilly says Phase 3 will use "an optimized escalation schedule." With CagriSema's FDA decision due in Q4, the amylin race now has parallel, comparable milestones.
What to watch: The Phase 3 initiation announcement and its titration design — whether optimized titration fixes the discontinuation problem determines if 23.3% is deliverable.
The Consumer Pivot Becomes Official Strategy — New
Both incumbents reorganized around the idea that the moat is migrating from molecule potency to consumer experience.
"This is where serious condition prescription medication meets incredibly strong consumer demand"
— Novo CEO Mike Doustdar, Fierce Pharma
Novo unveiled a planned "Consumer Rx" segment at its September CMD and rebranded from "Novo Nordisk" to "Novo"; Lilly posted a "Sr Director, Aesthetic Health External Innovation" role signaling a move into appearance-adjacent categories (Fierce Pharma). Doustdar conceded the efficacy gap plainly — "Mounjaro was launched later and demonstrated higher maximum weight-loss rates, leading the market to perceive it as a 'next-generation drug'" — and reframed the fight around fat-vs-muscle preservation, adherence, and orals, where he claims "no company prepares as many oral treatments as we do" (Chosun Ilbo). Management-level confirmation that when efficacy differences compress, the battlegrounds become brand, DTC channels, and lifecycle adjacencies.
What to watch: Whether Lilly follows Novo with an explicit consumer-organization or aesthetics announcement.
Public Payer Coverage Expands Where Commercial Retreated — New
The coverage map is splitting into negotiated-discount states and everyone else.
"Indiana Medicaid will pay $85.16 of the $245 monthly cost per person, thanks to contributions from the federal government and manufacturer discounts"
— Indiana Capital Chronicle
Governor Braun directed Indiana's Medicaid program — covering 1.9 million Hoosiers — to opt into the CMS BALANCE model, with Ricks endorsing the move and naming Foundayo and Zepbound explicitly (Indiana Capital Chronicle). Context: only 13 state Medicaid programs covered GLP-1s for obesity at the start of 2026, down from 16, because standalone coverage collapses at list price — while BALANCE makes it viable by cutting net price to ~$85/month (ObesityIntel). Each opt-in converts a zero-reimbursement population into discounted volume, building a political floor under pricing even as commercial employers pull back.
What to watch: Which states opt into BALANCE next — Indiana's own eligibility criteria and timing are still being finalized.
Small Caps: One Delivers, One Grinds — Escalated
Viking bought time; Structure bled out. Viking started Part 2 of its VK2735 maintenance study — daily and weekly oral tablets plus every-other-week and monthly subcutaneous dosing, to hold weight loss from 21 weeks of weekly injection (PR Newswire; PR Newswire release) — but as ObesityIntel notes, "this is not the oral VK2735 Phase 3 programme," which remains guided to Q4 2026 and unannounced (ObesityIntel). The stock fell ~3%; the market wants the registrational trial.
Structure's slide — last cycle's open thread — is resolved: it's a grind, not a catalyst. GPCR printed a 52-week low of $25.56 with an RSI of 1, and ObesityIntel's dated check found "no dated corporate change" at Structure — or Lilly, Amgen, or Altimmune — between September 29 and October 7 (ObesityIntel). The repricing is the oral GLP-1 premium compressing as Foundayo scales at $149; the Q4 SWITCH and Body Composition readouts are now the binary events.
What to watch: Viking's oral VK2735 Phase 3 initiation before year-end — the watch stays open and inside its window.
What surprised us
- The Oct 2 Foundayo surge now looks like noise. [UPDATED] A 21% spike that fully reverses a week later, in a class-wide down week, suggests payback or channel dynamics rather than a clean ramp — the "30% share" trigger got further away, not closer (Fierce Pharma tracker).
- The patent cliff is a 2031 story, not a 2037 story. [NEW] Revoking a formulation patent with no divisionals — after the board had preliminarily leaned toward maintaining it — should make Novo's remaining EU patent estate feel less secure than the docket suggests (JUVE Patent).
- The litigation overhang is big but inert. [NEW] Roughly 4,025 actions in the gastroparesis MDL and ~247 in the NAION MDL, no trial, no settlement, first bellwether expected late 2026–2027 — as ObesityIntel puts it, until a verdict attaches a number, "this is a dated calendar item, not a valuation input" (ObesityIntel).
- EloraTZP's tolerability asterisk is bigger than the headline suggests. [NEW] Up to 27% AE discontinuation is a real deliverability problem, and Lilly's entire Phase 3 design bet is that optimized titration fixes it.
Open threads
Status of last cycle's threads: the Structure Therapeutics slide is closed — resolved in the body as a thesis-compression grind with no discrete catalyst. The Foundayo-30% thread was dropped from the list — the body treats it as paused (the trigger receded), not resolved. The Medicare Bridge thread disappeared entirely, along with the Bridge enrollment data itself.